2상모집 중
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
연구 개요
The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating HER2-negative (HER2-low or HER2-0) metastatic breast cancer. The names of the study drugs involved in this study are: * Datopotamab deruxtecan (a type of antibody drug conjugate) * Trastuzumab deruxtecan (a type of antibody drug conjugate)
- 스폰서
- 협력: 아스트라제네카
- 적응증
- Breast Cancer, HER2-low Breast Cancer, Metastatic Breast Cancer, HER2-negative Breast Cancer
- 중재
- Trastuzumab Deruxtecan, Datopotamab Deruxtecan
- 목표 등록
- 357명
- 시작일
- 2024-10-29
- 완료(예정)
- 2038-08-01
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.